Sugi Predict

Sugi Predict / Compounds / SCHEMBL351208

SCHEMBL351208

SCHEMBL351208

CC1(C)CC2(CC(C)(C)P1c1ccc3ccccc3c1-c1cccc3ccccc13)OCCO2

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ DHFR P00374 1/20 0.32
▸ KDM4E B2RXH2 3/20 0.32
▸ CHRNA1 P02708 1/20 0.32
▸ CHRNG P07510 1/20 0.32
▸ CHRNB1 P11230 1/20 0.32
▸ CHRNB2 P17787 1/20 0.32
▸ SLC6A2 P23975 1/20 0.32
▸ CHRNB4 P30926 1/20 0.32
▸ SLC6A4 P31645 1/20 0.32
▸ CHRNA3 P32297 1/20 0.32
▸ CHRNA4 P43681 1/20 0.32
▸ SLC6A3 Q01959 1/20 0.32
▸ CHRND Q07001 1/20 0.32
▸ GSK3B P49841 1/20 0.32
▸ ADK P55263 1/20 0.32
▸ C5AR1 P21730 1/20 0.31
▸ ALDH1A1 P00352 3/20 0.31
▸ HPGD P15428 2/20 0.31
▸ SMN1; SMN2 Q16637 2/20 0.31
▸ MAPT P10636 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL370175 0.82 MAOA (0.39) KDM4ECHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL349967 0.82 MAPT (0.51) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL24535271 0.80 DHFR (0.35) DHFRKDM4ESLC6A2SLC6A4SLC6A3
SCHEMBL352055 0.80 MAPT (0.46) KDM4EALDH1A1HPGDSMN1; SMN2MAPT
SCHEMBL350498 0.78 DNMT1 (0.39) DHFRKDM4EGSK3BADKALDH1A1
SCHEMBL24535255 0.76 — —
SCHEMBL352304 0.71 HTR7 (0.36) KDM4EGSK3BALDH1A1SMN1; SMN2MAPT
SCHEMBL10177371 0.70 MEN1 (0.31) HPGDSMN1; SMN2CYP1A2CYP2C19MEN1
SCHEMBL10280919 0.70 KDM4E (0.32) KDM4ECHRNA1CHRNGCHRNB1CHRNB2
SCHEMBL350079 0.68 NSD2 (0.32) ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2593226-B1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBVIE IRELAND UNLIMITED CO (IE) 2018-11-14 — — EP claimed
EP-2593439-B1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS ABBVIE BAHAMAS LTD (BS) 2016-08-17 — — EP claimed
US-9381508-B2 Phosphine ligands for catalytic reactions ABBVIE INC. (US) 2016-07-05 — — US claimed
US-9255074-B2 Process for preparing antiviral compounds ABBVIE INC. (US) 2016-02-09 — — US claimed
US-20150360215-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBVIE INC. 2015-12-17 — — US claimed
US-9200021-B2 Phosphine ligands for catalytic reactions ABBVIE INC. (US) 2015-12-01 — — US claimed
EP-2887941-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS AbbVie Inc. (US) 2015-07-01 — — EP claimed
US-20150152126-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBVIE INC. 2015-06-04 — — US claimed
US-8895737-B2 Process for preparing antiviral compounds ABBVIE INC. 2014-11-25 — — US claimed
US-8841487-B2 Phosphine ligands for catalytic reactions ABBVIE INC. (US) 2014-09-23 — — US claimed
WO-2014031791-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS ABBVIE INC. (US) 2014-02-27 — — WO claimed
US-20130224149-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS ABBVIE INC. (US) 2013-08-29 — — US claimed
US-20120022252-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBOTT LABORATORIES (US) 2012-01-26 — — US claimed
US-20120014913-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-01-19 — — US claimed
WO-2022132048-A1 PHOSPHORUS COMPOUNDS AND METHODS THEREOF AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2022-06-23 — — WO disclosed
EP-3461556-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS AbbVie Ireland Unlimited Company (IE) 2019-04-03 — — EP disclosed
EP-3461556-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS AbbVie Ireland Unlimited Company (IE) 2019-04-03 — — EP disclosed
US-20120014913-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-01-19 — — US disclosed
WO-2012009699-A2 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS ABBOTT LABORATORIES (US) 2012-01-19 — — WO disclosed
WO-2012009698-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS ABBOTT LABORATORIES (US) 2012-01-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130224149-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS HAVCR2, RNASE1, MAVS DHFR 1487/4885KDM4E 3729/4885CHRNA1 4855/4885
US-20150152126-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS PHOSPHO1, PLCG2, PPIP5K2 DHFR 1060/4885KDM4E 3762/4885CHRNA1 4403/4885
US-20150360215-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS PHOSPHO1, PLCG2, PPIP5K2 DHFR 1060/4885KDM4E 3762/4885CHRNA1 4403/4885
US-20120014913-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS HAVCR2, MAVS, RNASE1 DHFR 1841/4885KDM4E 3572/4885CHRNA1 4858/4885
US-20120022252-A1 PHOSPHINE LIGANDS FOR CATALYTIC REACTIONS PHOSPHO1, PPIP5K2, ITPA DHFR 326/4885KDM4E 3814/4885CHRNA1 4392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.